XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Operating activities    
Net loss $ (250,739) $ (305,931)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Loss from equity method investment 25,500  
Depreciation and amortization 10,203 4,817
Amortization of investment discount (premiums) (4,308) (28)
In-process research and development charge   154,953
Stock-based compensation expense 61,822 28,068
Change in operating lease right-of-use assets 6,237 6,781
Change in fair value of derivative liabilities (20,900) 8,400
Change in fair value of contingent consideration liabilities 543 (9,553)
Change in fair value of non-controlling equity investments 1,378 (21,960)
Other 3 63
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (7,192) 733
Other long-term assets   (197)
Accounts payable (527) (1,341)
Accrued expenses and other liabilities (25,376) 2,818
Operating lease liabilities 13,496 15,208
Collaboration receivable 300,000  
Deferred revenue (15,883) 49,224
Other long-term liabilities (2,539) (153)
Net cash provided by (used in) operating activities 91,718 (68,098)
Investing activities    
Purchases of property and equipment (40,690) (33,442)
Purchases of marketable securities (1,378,609) (606,746)
Maturities of marketable securities 844,524 422,920
Net cash acquired from Guide   620
Net cash used in investing activities (574,775) (216,648)
Financing activities    
Proceeds from issuance of common shares, net of commissions 76,365 737,205
Proceeds from issuances of stock under ESPP 3,076  
Payment of equity offering costs (134) (8,688)
Repayment of equipment financings (1,697) (1,576)
Proceeds from exercise of stock options 1,968 7,657
Net cash provided by financing activities 79,578 734,598
Net change in cash, cash equivalents and restricted cash (403,479) 449,852
Cash, cash equivalents and restricted cash—beginning of period 572,740 177,011
Cash, cash equivalents and restricted cash—end of period 169,261 626,863
Supplemental disclosure of cash flow information:    
Cash paid for interest 300 443
Supplemental disclosure of noncash investing and financing activities:    
Property and equipment additions in accounts payable and accrued expenses 5,658 7,515
Operating lease liabilities arising from obtaining right-of-use assets 35,877 24,164
Non-cash contribution of intellectual property to Orbital Therapeutics Inc. $ 25,500  
Fair value of common stock issued to settle success payment liability   30,000
Equity issuance costs in accounts payable and accrued expenses   118
Contingent consideration liabilities assumed in asset acquisition   36,513
Fair value of equity instruments issued in connection with asset acquisition   $ 120,032